Plus   Neg

Viking Therapeutics Inc. (VKTX) Has Surged To A New High On Study Results

Viking Therapeutics Inc. (VKTX) announced Tuesday morning that its Phase 2 study of VK2809, in patients with non-alcoholic fatty liver disease, achieved its primary endpoint.

Viking Therapeutics has gapped open sharply higher this morning and is now up 12.16 at $22.55 on above average volume. The stock has soared past resistance and has set a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT